Arcutis Biotherapeutics Stock (NASDAQ:ARQT)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$10.24

52W Range

$1.76 - $13.17

50D Avg

$9.56

200D Avg

$9.51

Market Cap

$1.19B

Avg Vol (3M)

$1.95M

Beta

1.19

Div Yield

-

ARQT Company Profile


Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

296

IPO Date

Jan 31, 2020

Website

ARQT Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22
Other Revenue--
Product--

Fiscal year ends in Dec 23 | Currency in USD

ARQT Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income---
Net Income---
EBITDA---
Basic EPS---
Diluted EPS---

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 07, 24 | 2:24 AM
Q2 24Aug 15, 24 | 12:43 AM
Q1 24May 14, 24 | 7:47 PM

Peer Comparison


TickerCompany
GRCLGracell Biotechnologies Inc.
XFORX4 Pharmaceuticals, Inc.
VECTVectivBio Holding AG
APLSApellis Pharmaceuticals, Inc.
DAWNDay One Biopharmaceuticals, Inc.
ERASErasca, Inc.
SPROSpero Therapeutics, Inc.
TERNTerns Pharmaceuticals, Inc.
BOLTBolt Biotherapeutics, Inc.
INZYInozyme Pharma, Inc.
GLUEMonte Rosa Therapeutics, Inc.
DSGNDesign Therapeutics, Inc.
ABOSAcumen Pharmaceuticals, Inc.
NLTXNeurogene Inc.
CHRSCoherus BioSciences, Inc.
AMLXAmylyx Pharmaceuticals, Inc.
MIRMMirum Pharmaceuticals, Inc.